"This award reaffirms Granules India’s commitment to “Healing lives responsibly through pioneering green science,” as the company strives to make a positive impact at every step of its sustainability journey. Granules India is dedicated to achieving Net Zero emissions by 2050, in alignment with the Science Based Targets initiative (SBTi) and the United Nations’ Sustainable Development Goals (SDGs). Granules’ sustainability strategy emphasizes reducing Scope 1, 2, and 3 emissions, expanding renewable energy usage, and minimizing waste. These initiatives are supported by a robust governance framework led by a highly experienced Board of Directors, ensuring the highest standards of ethical conduct and transparency," the Company stated.
Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, commented on the award, saying, “Receiving the Golden Peacock Award for Sustainability is a proud moment for all of us at Granules. It reflects our commitment to embedding sustainability at the heart of our operations. As we strive to achieve Net Zero by 2050, our focus remains on pioneering green science and reducing our environmental impact in ways that benefit both our business and society. This recognition reaffirms our commitment to ethical governance and to advancing a responsible, sustainable future.”
Read also: Granules India appoints Ramraj Rangarajulu as President, Head of Formulations Operations
Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered in Hyderabad. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semiregulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
Read also: Granules India unveils Mobile Cancer Screening Unit at AIG Hospitals
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.